Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04118387 · ClinicalTrials.gov registry record · Phase 4
Central Sleep Apnea : Physiologic Mechanisms to Inform Treatment
A Phase 4 study of Sleep Disordered Breathing and Able Bodied, sponsored by VA Office of Research and Development.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT04118387 is a Phase 4 study of Sleep Disordered Breathing and Able Bodied that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 200 participants, roughly in line with the 188-participant average among 19 other Sleep Disordered Breathing trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT04118387, a Phase 4 study of Sleep Disordered Breathing and Able Bodied, is actively recruiting participants, sponsored by VA Office of Research and Development.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
Central sleep apnea (CSA) is common in patients with heart failure and those using opioid analgesics. Unfortunately, effective treatment of central apnea remains elusive, pressure therapy given the modest efficiency of positive airway pressure therapy. The focus of this proposal is to identify mechanistic pathways to guide future therapeutic interventions for central sleep apnea based on the strong premise that multi-modality therapy will normalize respiration and hence mitigate adverse long-term consequences of CSA. The investigators' proposed studies will test combination therapies, including positive airway pressure (PAP) plus a pharmacological agent who have heart failure or are using opioid analgesics. The investigators anticipate that findings will inform future clinical trials to improve care and quality of life among Veterans suffering from central sleep apnea, which remains difficult to treat using existing approaches.
Conditions Studied
Interventions
- DRUG Acetazolamide + supplemental oxygen + PAP therapy
- DRUG Zolpidem + PAP therapy
- DRUG Buspirone + PAP therapy
Study Locations (1)
Michigan
- John D. Dingell VA Medical Center, Detroit, MI - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2021-01-07 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04118387
The ClinicalTrials.gov registry entry for NCT04118387 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 188-participant average among 19 other Sleep Disordered Breathing trials with a reported enrollment target. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Sleep Disordered Breathing appearing as the primary indexed condition, and to 3 interventions - of which Acetazolamide + supplemental oxygen + PAP therapy is the first listed.
NCT04118387 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT04118387 about?
NCT04118387 is a clinical study titled "Central Sleep Apnea : Physiologic Mechanisms to Inform Treatment". Central sleep apnea (CSA) is common in patients with heart failure and those using opioid analgesics. Unfortunately, effective treatment of central apnea remains elusive, pressure therapy given the modest efficiency of positive airway pressure therapy. The focus of this proposal is to identify mecha...
What is the current status of trial NCT04118387?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 200 participants. The study started on 2021-01-07. Estimated completion is 2026-12-31.
What conditions does trial NCT04118387 study?
This clinical trial studies the following conditions: Sleep Disordered Breathing, Able Bodied.
What interventions are being tested in trial NCT04118387?
The interventions under investigation include: Acetazolamide + supplemental oxygen + PAP therapy (DRUG), Zolpidem + PAP therapy (DRUG), Buspirone + PAP therapy (DRUG).
Who is sponsoring clinical trial NCT04118387?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04118387 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sleep Disordered Breathing
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Optimization of Pediatric Tonsillectomy to IMprove AnaLgesia
RECRUITING · Phase 4
-
Sleep and Breathing in the General Population - Chemical Stimuli
COMPLETED · Phase 4
-
Evaluating the Genetics and Immunology of Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis (PFAPA) Syndrome and Other Tonsil Disorders
RECRUITING
-
Sleep Disordered Breathing With Opioid Use
RECRUITING · Phase 1
-
Belun Ring Platform With an Improved Algorithm for OSA Assessment
RECRUITING · NA
-
Lateral Pharyngoplasty Outcomes in Children Undergoing Tonsillectomy
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.